Last update May 13, 2019

Phenazopyridine Hydrochloride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

An azo dye with analgesic effects on the urinary tract mucosa.
One of its metabolites is paracetamol.
It may discolour body fluids orange.
Oral administration 3 times a day.

Since the last update we have not found any published data on its excretion in breast milk.

It may cause kidney damage (Singh 2014) and methemoglobinemia (Banimahd 2016, Gold 2003).

There are few studies on its pharmacokinetics and it has limited efficacy.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity or glucose-6PD deficiency.

Alternatives

  • Ibuprofen (Safe substance and/or breastfeeding is the best option.)
  • Paracetamol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Phenazopyridine Hydrochloride is also known as


Phenazopyridine Hydrochloride in other languages or writings:

Group

Phenazopyridine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Phenazopyridine Hydrochloride in its composition:

List of 28 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 250 daltons
pKa 5.1 -
Tmax 2.48 ± 0.50 hours
T½ 9.41 ± 2.04 hours

References

  1. Banimahd F, Loo T, Amin M, Ahadiat OR, Chakravarthy B, Lotfipour S. A Rare but Important Clinical Presentation of Induced Methemoglobinemia. West J Emerg Med. 2016 Abstract
  2. Singh M, Shailesh F, Tiwari U, Sharma SG, Malik B. Phenazopyridine associated acute interstitial nephritis and review of literature. Ren Fail. 2014 Abstract
  3. Li KJ, Chen QH, Zhang Z, Zhou P, Li P, Liu J, Zhu J. Determination of phenazopyridine in human plasma by GC-MS and its pharmacokinetics. J Chromatogr Sci. 2008 Abstract Full text (link to original source) Full text (in our servers)
  4. Gold NA, Bithoney WG. Methemoglobinemia due to ingestion of at most three pills of pyridium in a 2-year-old: case report and review. J Emerg Med. 2003 Abstract

Total visits

131,624

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM